{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T23:33:37Z","timestamp":1773876817440,"version":"3.50.1"},"reference-count":104,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.cyto.2016.10.012","type":"journal-article","created":{"date-parts":[[2016,10,27]],"date-time":"2016-10-27T21:00:31Z","timestamp":1477602031000},"page":"33-41","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"special_numbering":"C","title":["The promise of Janus kinase inhibitors in the treatment of hematological malignancies"],"prefix":"10.1016","volume":"98","author":[{"given":"Emilee","family":"Senkevitch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Durum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.cyto.2016.10.012_b0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/BJ20140712","article-title":"The molecular regulation of Janus kinase (JAK) activation","volume":"462","author":"Babon","year":"2014","journal-title":"Biochem. J."},{"issue":"2","key":"10.1016\/j.cyto.2016.10.012_b0010","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1056\/NEJMra1202117","article-title":"JAKs and STATs in immunity, immunodeficiency, and cancer","volume":"368","author":"O\u2019Shea","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.cyto.2016.10.012_b0015","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1038\/onc.2012.347","article-title":"JAK\/STAT signaling in hematological malignancies","volume":"32","author":"Vainchenker","year":"2013","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.cyto.2016.10.012_b0020","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1365-2141.2006.06206.x","article-title":"The role of Janus kinases in haemopoiesis and haematological malignancy","volume":"134","author":"Khwaja","year":"2006","journal-title":"Br. J. Haematol."},{"issue":"5237","key":"10.1016\/j.cyto.2016.10.012_b0025","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1126\/science.270.5237.797","article-title":"Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development","volume":"270","author":"Russell","year":"1995","journal-title":"Science (New York, N.Y.)"},{"issue":"4","key":"10.1016\/j.cyto.2016.10.012_b0030","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.immuni.2012.03.016","article-title":"Inborn errors of human JAKs and STATs","volume":"36","author":"Casanova","year":"2012","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.cyto.2016.10.012_b0035","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrrheum.2015.167","article-title":"Type I\/II cytokines, JAKs, and new strategies for treating autoimmune diseases","volume":"12","author":"Schwartz","year":"2016","journal-title":"Nat. Rev. Rheumatol."},{"issue":"Suppl. 2","key":"10.1016\/j.cyto.2016.10.012_b0040","doi-asserted-by":"crossref","first-page":"ii111","DOI":"10.1136\/annrheumdis-2012-202576","article-title":"Janus kinase inhibitors in autoimmune diseases","volume":"72","author":"O\u2019Shea","year":"2013","journal-title":"Ann. Rheum. Dis."},{"issue":"12","key":"10.1016\/j.cyto.2016.10.012_b0045","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1177\/0091270010389469","article-title":"The pharmacokinetics, pharmacodynamics, and safety of orally dosed INCB018424 phosphate in healthy volunteers","volume":"51","author":"Shi","year":"2011","journal-title":"J. Clin. Pharmacol."},{"issue":"12","key":"10.1016\/j.cyto.2016.10.012_b0050","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","article-title":"Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis","volume":"363","author":"Verstovsek","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.cyto.2016.10.012_b0055","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1124\/dmd.110.033787","article-title":"Metabolism, excretion, and pharmacokinetics of [14C]INCB018424, a selective Janus tyrosine kinase 1\/2 inhibitor, in humans","volume":"38","author":"Shilling","year":"2010","journal-title":"Drug Metab. Dispos."},{"issue":"33","key":"10.1016\/j.cyto.2016.10.012_b0060","doi-asserted-by":"crossref","first-page":"3953","DOI":"10.1200\/JCO.2015.61.6474","article-title":"Polycythemia Vera: an appraisal of the biology and management 10 years after the discovery of JAK2 V617F","volume":"33","author":"Stein","year":"2015","journal-title":"J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.cyto.2016.10.012_b0065","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1182\/asheducation-2009.1.621","article-title":"Pathogenesis and management of essential thrombocythemia, Hematology\/the Education Program of the American Society of Hematology","author":"Beer","year":"2009","journal-title":"Am. Soc. Hematol. Educ. Program"},{"issue":"9","key":"10.1016\/j.cyto.2016.10.012_b0070","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1002\/ajh.23703","article-title":"Primary myelofibrosis: 2014 update on diagnosis, risk-stratification, and management","volume":"89","author":"Tefferi","year":"2014","journal-title":"Am. J. Hematol."},{"issue":"5","key":"10.1016\/j.cyto.2016.10.012_b0075","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.blre.2014.06.002","article-title":"The future of JAK inhibition in myelofibrosis and beyond","volume":"28","author":"Mascarenhas","year":"2014","journal-title":"Blood Rev."},{"issue":"1","key":"10.1016\/j.cyto.2016.10.012_b0080","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/sj.leu.2404955","article-title":"Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms","volume":"22","author":"Tefferi","year":"2008","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.cyto.2016.10.012_b0085","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1158\/1078-0432.CCR-11-3145","article-title":"Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis","volume":"18","author":"Mascarenhas","year":"2012","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.cyto.2016.10.012_b0090","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1177\/2040620715586527","article-title":"Clinical potential of pacritinib in the treatment of myelofibrosis","volume":"6","author":"Duenas-Perez","year":"2015","journal-title":"Therap. Adv. Hematol."},{"issue":"4","key":"10.1016\/j.cyto.2016.10.012_b0095","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.bcp.2009.04.025","article-title":"An inhibitor of Janus kinase 2 prevents polycythemia in mice","volume":"78","author":"Mathur","year":"2009","journal-title":"Biochem. Pharmacol."},{"issue":"17","key":"10.1016\/j.cyto.2016.10.012_b0100","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1056\/NEJMp058083","article-title":"A unifying mutation in chronic myeloproliferative disorders","volume":"352","author":"Goldman","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"17","key":"10.1016\/j.cyto.2016.10.012_b0105","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"9464","key":"10.1016\/j.cyto.2016.10.012_b0110","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)74230-6","article-title":"Genome, acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"issue":"7037","key":"10.1016\/j.cyto.2016.10.012_b0115","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"issue":"15","key":"10.1016\/j.cyto.2016.10.012_b0120","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1182\/blood-2009-04-214957","article-title":"Preclinical characterization of the selective JAK1\/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms","volume":"115","author":"Quintas-Cardama","year":"2010","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.cyto.2016.10.012_b0125","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/nrd3652","article-title":"Ruxolitinib","volume":"11","author":"Mesa","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"issue":"9","key":"10.1016\/j.cyto.2016.10.012_b0130","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.cyto.2016.10.012_b0135","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.cyto.2016.10.012_b0140","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1038\/leu.2013.71","article-title":"Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis","volume":"27","author":"Pardanani","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.cyto.2016.10.012_b0145","series-title":"ClinicalTrials.Gov [Internet]","article-title":"Momelotinib versus Ruxolitinib in Subjects With Myelofibrosis","author":"Gilead Sciences","year":"2000"},{"issue":"11","key":"10.1016\/j.cyto.2016.10.012_b0150","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1038\/leu.2011.148","article-title":"SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies","volume":"25","author":"Hart","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.cyto.2016.10.012_b0155","first-page":"2655","article-title":"Emerging treatment options for myelofibrosis: focus on pacritinib","volume":"9","author":"Chow","year":"2016","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.cyto.2016.10.012_b0160","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2147\/JBM.S51253","article-title":"Profile of pacritinib and its potential in the treatment of hematologic disorders","volume":"5","author":"Hatzimichael","year":"2014","journal-title":"J. Blood Med."},{"key":"10.1016\/j.cyto.2016.10.012_b0165","series-title":"ClinicalTrials.Gov [Internet]","article-title":"Oral Pacritinib versus Best Available Therapy to Treat Myelofibrosis","author":"CTI BioPharma","year":"2000"},{"key":"10.1016\/j.cyto.2016.10.012_b0170","series-title":"ClinicalTrials.Gov [Internet]","article-title":"Oral Pacritinib versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia","author":"CTI Biopharma","year":"2000"},{"issue":"1","key":"10.1016\/j.cyto.2016.10.012_b0175","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/bjh.12607","article-title":"Open-label study of oral CEP-701 (lestaurtinib) in patients with polycythaemia vera or essential thrombocythaemia with JAK2-V617F mutation","volume":"164","author":"Hexner","year":"2014","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.cyto.2016.10.012_b0180","series-title":"ClinicalTrials.Gov [Internet]","article-title":"CEP-701 (Lestaurtinib) in Myelofibrosis","author":"Hoffman","year":"2000"},{"key":"10.1016\/j.cyto.2016.10.012_b0185","series-title":"ClinicalTrials.Gov [Internet]","article-title":"Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis","author":"Cephalon","year":"2000"},{"issue":"1","key":"10.1016\/j.cyto.2016.10.012_b0190","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jpeds.2011.08.006","article-title":"Clinical and laboratory biology of childhood acute lymphoblastic leukemia","volume":"160","author":"Carroll","year":"2012","journal-title":"J. Pediatr."},{"issue":"6","key":"10.1016\/j.cyto.2016.10.012_b0195","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11912-016-0519-8","article-title":"Treatment of relapsed\/refractory acute lymphoblastic leukemia in adults","volume":"18","author":"Ronson","year":"2016","journal-title":"Curr. Oncol. Rep."},{"issue":"2","key":"10.1016\/j.cyto.2016.10.012_b0200","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s11912-009-0018-2","article-title":"Jak2 inhibitors: rationale and role as therapeutic agents in hematologic malignancies","volume":"11","author":"Sayyah","year":"2009","journal-title":"Curr. Oncol. Rep."},{"issue":"5341","key":"10.1016\/j.cyto.2016.10.012_b0205","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1126\/science.278.5341.1309","article-title":"A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia","volume":"278","author":"Lacronique","year":"1997","journal-title":"Science (New York, N.Y.)"},{"issue":"10","key":"10.1016\/j.cyto.2016.10.012_b0210","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1038\/ng.924","article-title":"Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia","volume":"43","author":"Zenatti","year":"2011","journal-title":"Nat. Genet."},{"issue":"5","key":"10.1016\/j.cyto.2016.10.012_b0215","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1084\/jem.20110580","article-title":"Gain-of-function mutations in interleukin-7 receptor-alpha (IL7R) in childhood acute lymphoblastic leukemias","volume":"208","author":"Shochat","year":"2011","journal-title":"J. Exp. Med."},{"issue":"4","key":"10.1016\/j.cyto.2016.10.012_b0220","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1182\/blood-2016-03-679209","article-title":"Therapeutic targeting of IL-7Ralpha signaling pathways in ALL treatment","volume":"128","author":"Cramer","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.cyto.2016.10.012_b0225","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1182\/blood-2013-10-529685","article-title":"Novel activating mutations lacking cysteine in type I cytokine receptors in acute lymphoblastic leukemia","volume":"124","author":"Shochat","year":"2014","journal-title":"Blood"},{"issue":"7380","key":"10.1016\/j.cyto.2016.10.012_b0230","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/nature10725","article-title":"The genetic basis of early T-cell precursor acute lymphoblastic leukaemia","volume":"481","author":"Zhang","year":"2012","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.cyto.2016.10.012_b0235","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1182\/blood-2014-06-580480","article-title":"Efficacy of JAK\/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia","volume":"125","author":"Maude","year":"2015","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.cyto.2016.10.012_b0240","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/cam4.194","article-title":"Interleukin-7 receptor-alpha gene mutations are not detected in adult T-cell acute lymphoblastic leukemia","volume":"3","author":"Rozovski","year":"2014","journal-title":"Cancer Med."},{"issue":"4","key":"10.1016\/j.cyto.2016.10.012_b0245","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1084\/jem.20072182","article-title":"Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia","volume":"205","author":"Flex","year":"2008","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.cyto.2016.10.012_b0250","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/j.1365-2141.2009.07912.x","article-title":"JAK1 mutations are not frequent events in adult T-ALL: a GRAALL study","volume":"148","author":"Asnafi","year":"2010","journal-title":"Br. J. Haematol."},{"issue":"5","key":"10.1016\/j.cyto.2016.10.012_b0255","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.18632\/oncotarget.2218","article-title":"Mutational spectrum of adult T-ALL","volume":"6","author":"Neumann","year":"2015","journal-title":"Oncotarget"},{"issue":"23","key":"10.1016\/j.cyto.2016.10.012_b0260","doi-asserted-by":"crossref","first-page":"9414","DOI":"10.1073\/pnas.0811761106","article-title":"JAK mutations in high-risk childhood acute lymphoblastic leukemia","volume":"106","author":"Mullighan","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"2","key":"10.1016\/j.cyto.2016.10.012_b0265","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ccr.2012.06.005","article-title":"Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia","volume":"22","author":"Roberts","year":"2012","journal-title":"Cancer Cell"},{"issue":"14","key":"10.1016\/j.cyto.2016.10.012_b0270","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1182\/blood-2012-02-413252","article-title":"Differences in signaling through the B-cell leukemia oncoprotein CRLF2 in response to TSLP and through mutant JAK2","volume":"120","author":"van Bodegom","year":"2012","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.cyto.2016.10.012_b0275","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1038\/ng.469","article-title":"Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia","volume":"41","author":"Mullighan","year":"2009","journal-title":"Nat. Genet."},{"issue":"13","key":"10.1016\/j.cyto.2016.10.012_b0280","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1182\/blood-2009-03-208397","article-title":"Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia","volume":"114","author":"Russell","year":"2009","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.cyto.2016.10.012_b0285","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1073\/pnas.0911726107","article-title":"Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia","volume":"107","author":"Yoda","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"5","key":"10.1016\/j.cyto.2016.10.012_b0290","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/bjh.13096","article-title":"Haematopoietic development and leukaemia in Down syndrome","volume":"167","author":"Roberts","year":"2014","journal-title":"Br. J. Haematol."},{"issue":"15","key":"10.1016\/j.cyto.2016.10.012_b0295","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1182\/blood-2011-11-394221","article-title":"Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children\u2019s Oncology Group study","volume":"119","author":"Chen","year":"2012","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.cyto.2016.10.012_b0300","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1038\/leu.2012.84","article-title":"Outcome in children with Down\u2019s syndrome and acute lymphoblastic leukemia: role of IKZF1 deletions and CRLF2 aberrations","volume":"26","author":"Buitenkamp","year":"2012","journal-title":"Leukemia"},{"issue":"9648","key":"10.1016\/j.cyto.2016.10.012_b0305","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1016\/S0140-6736(08)61341-0","article-title":"Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down\u2019s syndrome","volume":"372","author":"Bercovich","year":"2008","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.cyto.2016.10.012_b0310","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1111\/j.1365-2141.2008.07552.x","article-title":"Prevalence and clinical correlates of JAK2 mutations in Down syndrome acute lymphoblastic leukaemia","volume":"144","author":"Gaikwad","year":"2009","journal-title":"Br. J. Haematol."},{"issue":"9","key":"10.1016\/j.cyto.2016.10.012_b0315","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1038\/leu.2016.164","article-title":"The biology, pathogenesis and clinical aspects of acute lymphoblastic leukemia in children with Down syndrome","volume":"30","author":"Lee","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.cyto.2016.10.012_b0320","series-title":"ClinicalTrials.Gov [Internet]","article-title":"Phase l\/II Study of Ruxolitinib for Acute Leukemia","author":"MD Anderson Cancer Center","year":"2000"},{"key":"10.1016\/j.cyto.2016.10.012_b0325","series-title":"ClinicalTrials.Gov [Internet]","article-title":"A Phase 2 Study of Ruxolitinib with Chemotherapy in Children with Acute Lymphoblastic Leukemia","author":"Incyte","year":"2000"},{"issue":"2","key":"10.1016\/j.cyto.2016.10.012_b0330","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/ped.12865","article-title":"Acute myeloid leukemia in children: Current status and future directions","volume":"58","author":"Taga","year":"2016","journal-title":"Pediatr. Int.: Off. J. Jpn. Pediatr. Soc."},{"issue":"Suppl. 1","key":"10.1016\/j.cyto.2016.10.012_b0335","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1179\/102453312X13336169155619","article-title":"Molecular targeted therapy in acute myeloid leukemia","volume":"17","author":"Daver","year":"2012","journal-title":"Hematology"},{"issue":"8","key":"10.1016\/j.cyto.2016.10.012_b0340","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1517\/13543784.2011.589383","article-title":"A potential role of ruxolitinib in leukemia","volume":"20","author":"Naqvi","year":"2011","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"1","key":"10.1016\/j.cyto.2016.10.012_b0345","doi-asserted-by":"crossref","first-page":"127","DOI":"10.3390\/jcm4010127","article-title":"Pediatric AML: from biology to clinical management","volume":"4","author":"de Rooij","year":"2015","journal-title":"J. Clin. Med."},{"issue":"6","key":"10.1016\/j.cyto.2016.10.012_b0350","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/sj.leu.2404206","article-title":"JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained","volume":"20","author":"Steensma","year":"2006","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.cyto.2016.10.012_b0355","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.leukres.2010.07.031","article-title":"Myeloid blastic transformation of myeloproliferative neoplasms \u2013 a review of 112 cases","volume":"35","author":"Noor","year":"2011","journal-title":"Leuk. Res."},{"issue":"1","key":"10.1016\/j.cyto.2016.10.012_b0360","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1586\/17474086.2.1.17","article-title":"Lestaurtinib: a multi-targeted FLT3 inhibitor","volume":"2","author":"Fathi","year":"2009","journal-title":"Expert Rev. Hematol."},{"issue":"10","key":"10.1016\/j.cyto.2016.10.012_b0365","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1182\/blood-2006-04-015560","article-title":"A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy","volume":"108","author":"Knapper","year":"2006","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.cyto.2016.10.012_b0370","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1182\/blood-2015-05-567859","article-title":"The biology of pediatric acute megakaryoblastic leukemia","volume":"126","author":"Gruber","year":"2015","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.cyto.2016.10.012_b0375","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1093\/jnci\/dji026","article-title":"GATA1, cytidine deaminase, and the high cure rate of Down syndrome children with acute megakaryocytic leukemia","volume":"97","author":"Ge","year":"2005","journal-title":"J. Natl. Cancer Inst."},{"issue":"11","key":"10.1016\/j.cyto.2016.10.012_b0380","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1038\/ng.2759","article-title":"The landscape of somatic mutations in Down syndrome-related myeloid disorders","volume":"45","author":"Yoshida","year":"2013","journal-title":"Nat. Genet."},{"issue":"2","key":"10.1016\/j.cyto.2016.10.012_b0385","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/leu.2013.157","article-title":"JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasal-type natural killer cell lymphoma","volume":"28","author":"Bouchekioua","year":"2014","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.cyto.2016.10.012_b0390","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/modpathol.2008.207","article-title":"Recurrent numerical aberrations of JAK2 and deregulation of the JAK2-STAT cascade in lymphomas","volume":"22","author":"Meier","year":"2009","journal-title":"Mod. Pathol.: Off. J. U.S. Can. Acad. Pathol. Inc."},{"issue":"17","key":"10.1016\/j.cyto.2016.10.012_b0395","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","article-title":"Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma","volume":"116","author":"Green","year":"2010","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.cyto.2016.10.012_b0400","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.blre.2015.06.002","article-title":"Deregulated JAK\/STAT signalling in lymphomagenesis, and its implications for the development of new targeted therapies","volume":"29","author":"Scott","year":"2015","journal-title":"Blood Rev."},{"issue":"10","key":"10.1016\/j.cyto.2016.10.012_b0405","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1158\/1078-0432.CCR-13-3007","article-title":"Selective JAK2 inhibition specifically decreases Hodgkin lymphoma and mediastinal large B-cell lymphoma growth in vitro and in vivo","volume":"20","author":"Hao","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"33","key":"10.1016\/j.cyto.2016.10.012_b0410","doi-asserted-by":"crossref","first-page":"4161","DOI":"10.1200\/JCO.2012.42.5223","article-title":"Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes","volume":"30","author":"Younes","year":"2012","journal-title":"J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol."},{"issue":"13","key":"10.1016\/j.cyto.2016.10.012_b0415","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1182\/blood-2015-03-635235","article-title":"The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis","volume":"126","author":"Deininger","year":"2015","journal-title":"Blood"},{"issue":"7414","key":"10.1016\/j.cyto.2016.10.012_b0420","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/nature11303","article-title":"Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy","volume":"489","author":"Koppikar","year":"2012","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.cyto.2016.10.012_b0425","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ccell.2015.06.005","article-title":"Activity of the Type II JAK2 inhibitor CHZ868 in B cell acute lymphoblastic leukemia","volume":"28","author":"Wu","year":"2015","journal-title":"Cancer Cell"},{"issue":"26","key":"10.1016\/j.cyto.2016.10.012_b0430","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1182\/blood-2014-05-576652","article-title":"Cooperating JAK1 and JAK3 mutants increase resistance to JAK inhibitors","volume":"124","author":"Springuel","year":"2014","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.cyto.2016.10.012_b0435","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.celrep.2013.10.038","article-title":"Combined targeting of JAK2 and Bcl-2\/Bcl-xL to cure mutant JAK2-driven malignancies and overcome acquired resistance to JAK2 inhibitors","volume":"5","author":"Waibel","year":"2013","journal-title":"Cell Rep."},{"issue":"17","key":"10.1016\/j.cyto.2016.10.012_b0440","doi-asserted-by":"crossref","first-page":"3510","DOI":"10.1182\/blood-2012-03-415448","article-title":"Targeting JAK1\/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia","volume":"120","author":"Maude","year":"2012","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.cyto.2016.10.012_b0445","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1038\/leu.2012.96","article-title":"Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib\/multi-targeted inhibitors and JAK inhibitors","volume":"26","author":"Weisberg","year":"2012","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.cyto.2016.10.012_b0450","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1177\/2040620714565963","article-title":"Novel agents for the treatment of childhood acute leukemia","volume":"6","author":"Annesley","year":"2015","journal-title":"Therap. Adv. Hematol."},{"issue":"5","key":"10.1016\/j.cyto.2016.10.012_b0455","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1038\/leu.2015.350","article-title":"Dexamethasone treatment promotes Bcl-2 dependence in multiple myeloma resulting in sensitivity to venetoclax","volume":"30","author":"Matulis","year":"2016","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.cyto.2016.10.012_b0460","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nrc.2015.17","article-title":"Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies","volume":"16","author":"Delbridge","year":"2016","journal-title":"Nat. Rev. Cancer"},{"issue":"25","key":"10.1016\/j.cyto.2016.10.012_b0465","doi-asserted-by":"crossref","first-page":"3738","DOI":"10.1182\/blood-2014-05-574566","article-title":"ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia","volume":"124","author":"Peirs","year":"2014","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.cyto.2016.10.012_b0470","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1007\/s12185-010-0653-2","article-title":"Absence of gain-of-function JAK1 and JAK3 mutations in adult T cell leukemia\/lymphoma","volume":"92","author":"Kameda","year":"2010","journal-title":"Int. J. Hematol."},{"issue":"40","key":"10.1016\/j.cyto.2016.10.012_b0475","doi-asserted-by":"crossref","first-page":"12480","DOI":"10.1073\/pnas.1516208112","article-title":"Selective targeting of JAK\/STAT signaling is potentiated by Bcl-xL blockade in IL-2-dependent adult T-cell leukemia","volume":"112","author":"Zhang","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.cyto.2016.10.012_b0480","series-title":"Nathan and Oski\u2019s Hematology and Oncology of Infancy and Childhood","author":"Orkin","year":"2015"},{"issue":"31","key":"10.1016\/j.cyto.2016.10.012_b0485","doi-asserted-by":"crossref","first-page":"5175","DOI":"10.1200\/JCO.2008.21.2514","article-title":"Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children\u2019s oncology group study","volume":"27","author":"Schultz","year":"2009","journal-title":"J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.cyto.2016.10.012_b0490","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/S1470-2045(12)70377-7","article-title":"Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study","volume":"13","author":"Biondi","year":"2012","journal-title":"Lancet Oncol."},{"issue":"7","key":"10.1016\/j.cyto.2016.10.012_b0495","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/leu.2014.30","article-title":"Oncology, Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children\u2019s Oncology Group study AALL0031","volume":"28","author":"Schultz","year":"2014","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.cyto.2016.10.012_b0500","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.canlet.2014.02.009","article-title":"Towards precision medicine in childhood leukemia \u2013 insights from mutationally activated cytokine receptor pathways in acute lymphoblastic leukemia","volume":"352","author":"Izraeli","year":"2014","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.cyto.2016.10.012_b0505","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/MOP.0000000000000293","article-title":"Therapies on the horizon for childhood acute lymphoblastic leukemia","volume":"28","author":"Carroll","year":"2016","journal-title":"Curr. Opin. Pediatr."},{"issue":"6","key":"10.1016\/j.cyto.2016.10.012_b0510","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/ng.2287","article-title":"The pediatric cancer genome project","volume":"44","author":"Downing","year":"2012","journal-title":"Nat. Genet."},{"issue":"2","key":"10.1016\/j.cyto.2016.10.012_b0515","doi-asserted-by":"crossref","first-page":"77","DOI":"10.14348\/molcells.2016.2350","article-title":"An integrative approach to precision cancer medicine using patient-derived xenografts","volume":"39","author":"Cho","year":"2016","journal-title":"Mol. Cells"},{"issue":"5","key":"10.1016\/j.cyto.2016.10.012_b0520","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/nrc3944","article-title":"Examining the utility of patient-derived xenograft mouse models","volume":"15","author":"Aparicio","year":"2015","journal-title":"Nat. Rev. Cancer"}],"container-title":["Cytokine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104346661630552X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104346661630552X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,14]],"date-time":"2019-09-14T23:35:36Z","timestamp":1568504136000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S104346661630552X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":104,"alternative-id":["S104346661630552X"],"URL":"https:\/\/doi.org\/10.1016\/j.cyto.2016.10.012","relation":{},"ISSN":["1043-4666"],"issn-type":[{"value":"1043-4666","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The promise of Janus kinase inhibitors in the treatment of hematological malignancies","name":"articletitle","label":"Article Title"},{"value":"Cytokine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cyto.2016.10.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}